Survival outcomes associated with MGMT promoter methylation and temozolomide in gliosarcoma patients
Author:
Funder
National Cancer Institute
Publisher
Springer Science and Business Media LLC
Subject
Cancer Research,Neurology (clinical),Neurology,Oncology
Link
https://link.springer.com/content/pdf/10.1007/s11060-022-04016-5.pdf
Reference33 articles.
1. Iorgulescu JB, Sun C, Neff C, et al (2022) Molecular Biomarker-Defined Brain Tumors: Epidemiology, Validity, and Completeness in the United States. Neuro-Oncol. noac113. https://doi.org/10.1093/neuonc/noac113
2. Galanis E, Buckner JC, Dinapoli RP et al (1998) Clinical outcome of gliosarcoma compared with glioblastoma multiforme: North Central Cancer Treatment Group results. J Neurosurg 89:425–430. https://doi.org/10.3171/jns.1998.89.3.0425
3. Lutterbach J, Guttenberger R, Pagenstecher A (2001) Gliosarcoma: a clinical study. Radiother Oncol J Eur Soc Ther Radiol Oncol 61:57–64. https://doi.org/10.1016/s0167-8140(01)00415-7
4. Kozak KR, Mahadevan A, Moody JS (2009) Adult gliosarcoma: epidemiology, natural history, and factors associated with outcome. Neuro-Oncol 11:183–191. https://doi.org/10.1215/15228517-2008-076
5. Louis DN, Perry A, Wesseling P et al (2021) The 2021 WHO classification of tumors of the central nervous system: a summary. Neuro-Oncol 23:1231–1251. https://doi.org/10.1093/neuonc/noab106
Cited by 5 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Antigen presentation deficiency, mesenchymal differentiation, and resistance to immunotherapy in the murine syngeneic CT2A tumor model;Frontiers in Immunology;2023-12-28
2. Clinicopathological and Neuroimaging Features of Primary Gliosarcoma: A Case Series and Review of Literature;World Neurosurgery;2023-10
3. The evaluation of six genes combined value in glioma diagnosis and prognosis;Journal of Cancer Research and Clinical Oncology;2023-07-13
4. Association between MGMT Enhancer Methylation and MGMT Promoter Methylation, MGMT Protein Expression, and Overall Survival in Glioblastoma;Cells;2023-06-15
5. The predictive value of partial MGMT promoter methylation for IDH-wild-type glioblastoma patients;Neuro-Oncology Practice;2022-09-10
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3